Dov A Goldstein

Bio

Dr Goldstein serves as a Partner of Aisling Capital. Previously, Dr Goldstein was Executive Vice President and Chief Financial Officer of Vicuron Pharmaceuticals up until its acquisition by Pfizer for $1.9 billion. While at Vicuron Pharmaceuticals, he raised over $250 million dollars in an IPO, PIPE, Follow-on, and block trade transactions. He led the valuation and finance due diligence for the merger with Biosearch Italia (Nuovo mercato: BIO.MI), the first US and Italian public to public company merger. He also ran the investor relations and press relations efforts for the company. Prior to Vicuron, Dr Goldstein was Director of Venture Analysis at HealthCare Ventures. He also completed an internship in the Department of Medicine, at Columbia-Presbyterian Hospital. Dr Goldstein currently serves as a director of ADMA Biologics Inc, BioRelix Inc, CardioKine Inc, Cempra Pharmaceuticals Inc, Durata Therapeutics Inc, Esperion Therapeutics Inc and Topaz Pharmaceuticals Inc. Dr Goldstein received his MD from Yale School of Medicine. He received his MBA from Columbia Business School and his BS with honors from Stanford University.